Locally Ablative Radiation Therapy of a Primary Human Small Cell Lung Cancer Tumor Decreases the Number of Spontaneous Metastases in Two Xenograft Models

Frenzel, Thorsten; Siekmann, Jordana; Grohmann, Carsten; Valentiner, Ursula; Schmitz, Rüdiger; Riecken, Kristoffer; Schumacher, Udo; Lange, Tobias; Krüll, Andreas

doi:10.1016/j.ijrobp.2017.11.044

Cited by 2 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these treatments were thought for a localized treatment of primary tumors, it is also interesting to evaluate the effect of the treatments in the metastatic process, because inhibition of the primary tumor growth by these type of treatments might well reduce the large number of cells that primary tumors are continuously shedding to the circulation [71,72]. In our case, metastatic lesions at the mammary chain (loco-regional dissemination), lumbar lymph nodes (lymphatic dissemination) and lung (hematologic dissemination) were detected only in non-treated control mice (Sup.…”

Section: In Vivo Antitumor Efficacy and Tolerability Of Bc-nlcs-nh Filmsmentioning

confidence: 99%

Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment

Cacicedo

Islan

León

et al. 2018

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

The use of hybrid materials, where a matrix sustains nanoparticles controlling the release of the chemotherapeutic drug, could be beneficial for the treatment of primary tumors prior or after surgery. This localized chemotherapy would guarantee high drug concentrations at the tumor site while precluding systemic drug exposure minimizing undesirable side effects. We combined bacterial cellulose hydrogel (BC) and nanostructured lipid carriers (NLCs) including doxorubicin (Dox) as a drug model. NLCs loaded with cationic Dox (NLCs-H) or neutral Dox (NLCs-N) were fully characterized and their cell internalization and cytotoxic efficacy were evaluated in vitro against MDA-MB-231 cells. Thereafter, a fixed combination of NLCs-H and NLCs-N loaded into BC (BC-NLCs-NH) was assayed in vivo into an orthotopic breast cancer mouse model. NLCs-H showed low encapsulation efficiency (48%) and fast release of the drug while NLCs-N showed higher encapsulation (97%) and sustained drug release. Both NLCs internalized via endocytic pathway, while allowing a sustained release of the Dox, which in turn rendered IC50 values below of those of free Dox. Taking advantage of the differential drug release, a mixture of NLCs-N and NLCs-H was encapsulated into BC matrix (BC-NLCs-NH) and assayed in vivo, showing a significant reduction of tumor growth, metastasis incidence and local drug toxicities.

show abstract

Section: In Vivo Antitumor Efficacy and Tolerability Of Bc-nlcs-nh Filmsmentioning

confidence: 99%

Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment

Cacicedo

Islan

León

et al. 2018

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

“…Importantly, hydroxychloroquine (HCQ), a well-established inhibitor of autophagy, significantly suppressed HCC proliferation and recurrence induced by IRFA ( Zhao et al, 2018 ). Recently, Frenzel et al (2018) suggested that hypoxia-inducible factor (HIF), the key gene switch for adaptive responses to hypoxia, played an important role in the rapid aggressive recurrence of HCC after RFA. Currently, there is still a lack of narrative reviews on the role of HIF in the local ablation of HCC.…”

Section: Introductionmentioning

confidence: 99%

Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies

Xiao

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common digestive malignancies. HCC It ranges as the fifth most common cause of cancer mortality worldwide. While The prognosis of metastatic or advanced HCC is still quite poor. Recently, locoregional treatment, especially local ablation therapies, plays an important role in the treatment of HCC. Radiofrequency ablation (RFA) and high-intensity focused ultrasound (HIFU) ablation are the most common-used methods effective and feasible for treating HCC. However, the molecular mechanisms underlying the actions of ablation in the treatments for HCC and the HCC recurrence after ablation still are poorly understood. Hypoxia-inducible factor (HIF), the key gene switch for adaptive responses to hypoxia, has been found to play an essential role in the rapid aggressive recurrence of HCC after ablation treatment. In this review, we summarized the current evidence of the roles of HIF in the treatment of HCC with ablation. Fifteen relevant studies were included and further analyzed. Among them, three clinical studies suggested that HIF-1α might serve as a crucial role in the RAF treatment of HCC or the local recurrence of HCC after RFA. The remainder included experimental studies demonstrated that HIF-1, 2α might target the different molecules (e.g., BNIP3, CA-IX, and arginase-1) and signaling cascades (e.g., VEGFA/EphA2 pathway), constituting a complex network that promoted HCC invasion and metastasis after ablation. Currently, the inhibitors of HIF have been developed, providing important proof of targeting HIF for the prevention of HCC recurrence after IRFA and HIFU ablation. Further confirmation by prospective clinical and in-depth experimental studies is still warranted to illustrate the effects of HIF in HCC recurrence followed ablation treatment in the future.

show abstract

Locally Ablative Radiation Therapy of a Primary Human Small Cell Lung Cancer Tumor Decreases the Number of Spontaneous Metastases in Two Xenograft Models

Cited by 2 publications

References 52 publications

Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment

Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment

Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies

Contact Info

Product

Resources

About